ContraVir Pharmaceuticals (NASDAQ: CTRV) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare ContraVir Pharmaceuticals to related businesses based on the strength of its institutional ownership, risk, earnings, dividends, analyst recommendations, profitability and valuation.

Volatility and Risk

ContraVir Pharmaceuticals has a beta of 2.32, meaning that its share price is 132% more volatile than the S&P 500. Comparatively, ContraVir Pharmaceuticals’ rivals have a beta of 0.53, meaning that their average share price is 47% less volatile than the S&P 500.

Institutional & Insider Ownership

6.7% of ContraVir Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 4.2% of ContraVir Pharmaceuticals shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ContraVir Pharmaceuticals and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ContraVir Pharmaceuticals 0 0 2 0 3.00
ContraVir Pharmaceuticals Competitors 841 3190 11567 230 2.71

ContraVir Pharmaceuticals presently has a consensus target price of $4.00, indicating a potential upside of 809.09%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.62%. Given ContraVir Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe ContraVir Pharmaceuticals is more favorable than its rivals.

Valuation and Earnings

This table compares ContraVir Pharmaceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ContraVir Pharmaceuticals N/A -$14.89 million -0.90
ContraVir Pharmaceuticals Competitors $284.30 million $34.29 million 136.04

ContraVir Pharmaceuticals’ rivals have higher revenue and earnings than ContraVir Pharmaceuticals. ContraVir Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares ContraVir Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ContraVir Pharmaceuticals N/A -386.59% -97.30%
ContraVir Pharmaceuticals Competitors -5,266.10% -428.13% -38.73%

About ContraVir Pharmaceuticals

ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase IIa clinical candidate TXL, a novel potent analog of antiviral drug tenofovir and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.

Receive News & Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related companies with's FREE daily email newsletter.